Related Experiment Video
Updated: Oct 14, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective
Xiangling Chu1, Huiping Qiang2, Mengqing Xie1
1Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, School of Medicine, Tongji University, Shanghai, China.
Background:
Despite the remarkable clinical advance of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer, there are limited studies focused on evaluating efficacy of ICIs for patients with human epidermal growth factor receptor 2 (HER2)-mutant lung adenocarcinoma.
Methods:
We conducted a multicenter retrospective study of patients with HER2-mutant lung adenocarcinoma who received ICIs therapy at Shanghai Pulmonary Hospital, Shanghai Chest Hospital and the First Affiliated Hospital of Wenzhou Medical University between 2016 and 2021. Response was defined with reference to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Results:
Among the 26 patients enrolled in our study, the overall objective response rate (ORR) was 38.5%, disease control rate (DCR) was 84.6% and median progression-free survival (PFS) was 7.4 months. Majority of patients were treated with immunochemotherapy combination regimens (16/26, 61.5%), with a median PFS of 8.4 months. Among the 9 patients receiving ICIs-based therapy as first-line treatment, 5 patients had partial response (PR) and 4 patients had stable disease (SD), with a median PFS of 9.1 months. Of the entire cohort, 5 patients who received ICIs before epidermal growth factor receptor (EGFR)/HER2-targeting drugs achieved a median PFS of 8.4 months.
Conclusion:
Our retrospective study provides clinical evidence that front line of ICIs-based therapy is also worth considering for the treatment to improve survival outcomes of patients with HER2-mutant lung adenocarcinoma.
Insights
Immune checkpoint inhibitors (ICIs) show promise for HER2-mutant lung adenocarcinoma. First-line ICI-based therapy demonstrated encouraging survival outcomes in this patient group.
Area of Science:
- Oncology
- Immunotherapy
- Genomics in Cancer
Background:
- Limited data exists on immune checkpoint inhibitor (ICI) efficacy in HER2-mutant lung adenocarcinoma.
- HER2 mutations are a targetable driver in a subset of lung adenocarcinomas.
Purpose of the Study:
- To evaluate the efficacy of ICIs in patients with HER2-mutant lung adenocarcinoma.
- To assess response rates and survival outcomes with ICI therapy in this specific patient population.
Main Methods:
- Multicenter retrospective study (2016-2021) of 26 patients with HER2-mutant lung adenocarcinoma receiving ICIs.
- Response evaluation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Main Results:
- Overall objective response rate (ORR) was 38.5% and disease control rate (DCR) was 84.6%.
- Median progression-free survival (PFS) was 7.4 months; 8.4 months for immunochemotherapy.
- First-line ICI-based therapy showed a median PFS of 9.1 months.
Conclusions:
- First-line ICI-based therapy is a viable option for improving survival in HER2-mutant lung adenocarcinoma.
- These findings support further investigation of ICIs in this patient subgroup.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
